Company profile: Fidia Pharma
1.1 - Company Overview
Company description
- Provider of hyaluronic acid–based therapies for joint health, tissue repair, wound healing, ophthalmology, and aesthetic care, plus autologous biological therapy. Offers ophthalmic products (contact lenses, lens solutions, eye drops), gynaecological medicines (anti-infectives, ovarian stimulants), and treatments for skin lesions to restore the skin barrier. Italian multinational with R&D, manufacturing, marketing and sales capabilities.
Products and services
- Hyaluronic Acid Products: Engineers HA-based regenerative products applied to joint health and tissue repair across joint care, wound healing, ophthalmology, and aesthetic applications, focusing on hyaluronic acid’s therapeutic regenerative properties
- Regenerative Medicine: Develops HA-driven regenerative products for tissue repair and joint health, architecting therapies that leverage hyaluronic acid in biologically restorative applications across musculoskeletal and soft-tissue care
- Ophthalmic Products: Produces HA-focused eye health products including contact lenses, lens solutions, and eye drops, strengthened by acquisitions and partnerships to address ocular care needs with a comprehensive range of devices and formulations
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Fidia Pharma
Cambrex
HQ: United States
Website
- Description: Provider of end-to-end small molecule drug substance and drug product development and manufacturing, analytical services and testing, IND-enabling services, and process development. Supports research through commercial scale, covering various dosage forms, streamlining IND submissions, and ensuring regulatory compliance and product safety for small molecule therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cambrex company profile →
Mikart
HQ: United States
Website
- Description: Provider of integrated CDMO services, technology and support for the development, manufacturing and packaging of solid dose and non-sterile liquid pharmaceuticals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mikart company profile →
ProPharma
HQ: United States
Website
- Description: Provider of independent, single-source regulatory, compliance, pharmacovigilance, and medical information services for pharmaceutical, biotechnology, and medical device companies; offering RCO custom solutions across the full product lifecycle, tailored MedTech solutions from concept to market, full-service Oncology CRO capabilities, global lifecycle solutions, and Prodigy technology to de-risk decision making and drive value.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ProPharma company profile →
Biofer
HQ: Italy
Website
- Description: Provider of organic and inorganic medicinal chemicals and active pharmaceutical ingredients, including iron complexes for anemia, heparins and glycosaminoglycans as antithrombotics to prevent blood clots, steroids for anti-shock and antiallergic uses, folinates as antitumor adjuvants supporting cancer therapies, and enzymes as anti-inflammatories.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biofer company profile →
Explora BioLabs
HQ: United States
Website
- Description: Provider of preclinical, AAALAC-accredited vivarium rental facilities and contract vivarium operation services, delivering turnkey in vivo facilities, management, and related services for biopharmaceutical clients in biotech-dense areas, with vivarium management ensuring maintenance and compliance and CRO options to support early-stage research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Explora BioLabs company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Fidia Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Fidia Pharma
2.2 - Growth funds investing in similar companies to Fidia Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Fidia Pharma
4.2 - Public trading comparable groups for Fidia Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →